Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
28°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Atai Life Sciences N.V.
(NQ:
ATAI
)
1.610
+0.090 (+5.92%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Atai Life Sciences N.V.
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
26
27
Next >
"Rags-To-Riches" Portfolio Update: Week Ending January 20, 2023
January 22, 2023
My new portfolio of 14 cannabis, psychedelic and plant-based food stocks were cumulatively pretty awful in 2022, thus could well offer high returns in 2023.
Via
Talk Markets
Largest Psychedelic Stocks +3% This Week; Now +15% YTD
January 21, 2023
Our Psychedelic Drug Stocks Index tracks the six largest psychedelic stocks, by market capitalization, that research the treatment of mental illnesses based on the use of one or more of 10 different...
Via
Talk Markets
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
January 20, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 19, 2023
January 19, 2023
Via
Benzinga
This Analyst Still Has Confidence In Atai Life Sciences' Pipeline Despite Recent Setbacks
January 19, 2023
Via
Benzinga
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
January 18, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 17, 2023
January 17, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 11, 2023
January 11, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 10, 2023
January 10, 2023
Via
Benzinga
Psyched: Psychedelics In Davos, Prince Harry In The 90s, Cathie Wood's Latest Moves And More
January 17, 2023
Psychedelics Take Center Stage In Davos Psychedelics will lead the conversation inside the Davos House of Health for a second year in a row this January.
Via
Benzinga
GH Research, Cybin Among Top Psychedelic Movers Of Today
January 16, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 13, 2023
January 13, 2023
Via
Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
January 12, 2023
Via
Benzinga
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
January 12, 2023
After atai Life Sciences (NASDAQ: ATAI) shared the results of subsidiary Perception Neuroscience’s Phase 2 trial of R-ketamine compound for TRD, the psyche
Via
Benzinga
What 4 Analyst Ratings Have To Say About ATAI Life Sciences
January 09, 2023
Via
Benzinga
ATAI Life Sciences, Cybin Among Top Psychedelic Movers Of Today
January 06, 2023
Via
Benzinga
Atai Life Sciences' Depression Candidate Faces Trial Setback, Shares Nosedive
January 06, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 5, 2023
January 05, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 9, 2023
January 09, 2023
Via
Benzinga
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
January 09, 2023
From
atai Life Sciences
Via
GlobeNewswire
My "Rags-To-Riches" Portfolio For 2023: An Introduction
January 08, 2023
The performance of cannabis, psychedelic and plant-based food stocks in 2022 were just horrible; is there any way to go but up?
Via
Talk Markets
atai Life Sciences' Drug Trial For Depression Fails To Deliver Expected Results, Stock Plunges
January 06, 2023
Clinical-stage psychedelics biotech atai Life Sciences (NASDAQ: ATAI) shared the results of its NYC-based subsidiary NYC-based Perception Neuroscience’s Phase 2a study of proprietary R-ketamine PCN-101...
Via
Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
January 04, 2023
Via
Benzinga
Dow Jumps 700 Points; S&P 500 Rises Over 2%
January 06, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 700 points on Friday.
Via
Benzinga
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 06, 2023
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.
Via
Benzinga
Nasdaq Gains 1.5%; Fate Therapeutics Shares Plunge
January 06, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 550 points on Friday.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
January 06, 2023
During Friday's trading, 71 companies set new 52-week lows.
Via
Benzinga
Greenbrier, Fate Therapeutics, AnaptysBio And Some Other Big Stocks Moving Lower On Friday
January 06, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 500 points on Friday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Dow Rises Over 300 Points; US Adds 223,000 Jobs In December
January 06, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday.
Via
Benzinga
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
January 06, 2023
From
atai Life Sciences
Via
GlobeNewswire
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
